, , and , respectively). In conclusion, there was P ! .0001 P p .026 P ! .0001 significant correlation between AdV and HC in the patients we studied.
Late-onset hemorrhagic cystitis (HC) is a common complication in patients who undergo bone marrow transplantation (BMT) that is mainly attributed to viral infection. BK virus (BKV) is frequently isolated from such patients and thus has been considered to be the main pathogen of HC [1] .
Adenovirus (AdV) is a known pathogen for HC and is considered to be an important pathogen of HC in patients who have undergone BMT [2] . However, we found no reports that examined AdV and BKV simultaneously in cases in which AdV seemed to be the prominent pathogen for HC. Therefore, the possibility remained that the incidence of BKV infection is different, such that AdV would be the major pathogen in those reports. In addition, both BKV and AdV are excreted into the urine when no symptoms of infection are present, a fact that may elude researchers and make distinguishing the responsible pathogen difficult.
This study examines the risk factors for HC and the significance of the viruses that were obtained from patients both with and without HC after they underwent BMT. We also evaluated the significance of JC virus (JCV) because BKV and JCV are both polyomaviruses and may behave similarly, despite data reported elsewhere that suggest otherwise [3] .
PATIENTS AND METHODS

Study population.
The study participants were consecutive patients 115 years of age who underwent [5, 6] . c From [7, 8] .
BMT at the Hematology Division of Tokyo Metropolitan Komagome Hospital from 1986 through 1998. A total of 207 patients received either allogeneic bone marrow transplants (203 patients) or peripheral stem cell transplants (4 patients), of which 54 were from unrelated donors. A total of 71 patients underwent autologous BMT or peripheral stem cell transplantation. Another 4 patients underwent syngeneic transplantation. Bone marrow transplantation. Preparative regimens were selected mainly with regard to the primary diseases of the patients and the source of the bone marrow. Patients with acute myelogenous leukemia and chronic myelogenous leukemia were treated with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). Total lymphoid irradiation (700 cGy) was also used to treat patients who received marrow from unrelated donors. Patients with severe aplastic anemia were treated with cyclophosphamide (200 mg/kg) and total lymphoid irradiation, and those with acute lymphoblastic leukemia were treated with cytosine arabinoside (8 g/m 2 ) and cyclophosphamide (120 mg/ kg), followed by total body irradiation of 1200 cGy. Other diseases were treated with busulfan/cyclophosphamide or cytosine arabinoside/cyclophosphamide/total body irradiation.
Four doses of sodium 2-mercaptoethane sulfonate (mesna; 15 mg/kg) were administered just before and 1, 2, and 4 h after the administration of cyclophosphamide to prevent HC. All patients who received allogeneic transplants received cyclosporine or tacrolimus with or without short-term methotrexate as prophylaxis against graft-versus-host disease (GVHD). As prophylaxis for herpesvirus infection, acyclovir was administered at a dosage of 750 mg/d from day Ϫ5 to day 25 after the patients underwent BMT. Immunoglobulins were not used after the patient underwent BMT.
Definition of HC and urine specimen collection. To exclude the patients with HC caused by the preparative regimen, only those patients who developed gross hematuria de novo 10 days after they underwent BMT and who did not have bacteriuria were defined as having HC in this study.
Urinalysis was performed 2 to 3 times per week. Urine specimens for viral culture were obtained from the patients with HC within 3 days of diagnosis. Urine specimens for PCR were also obtained from 26 consecutive patients who underwent allogeneic BMT from April through December 1998. These specimens were obtained before and once per week for 5 weeks after the patients underwent BMT, followed by sampling at 8 and 12 weeks after BMT, if possible. In addition, 14 available urine samples from 19 patients with HC who underwent transplantation from July 1995 through February 1998 were evaluated by means of PCR and viral culture.
Urine virus culture. Urine samples were cocultured with MRC-5, MA 104, and Hep 2 cells. When cytopathic signs of viral infection appeared, the cells were collected and identified to the species level with use of monoclonal antibodies to AdV (Dennka Seiken). Cultures continued to be performed for up to 2 months when pathological changes were absent. These culture methods are not available to detect BKV and JCV.
PCR of urine samples. PCR was selected for evaluation of BKV and JCV, which could not be detected by means of the usual viral culture. After 40 mL of urine was sedimented at 800g, the supernatant was further sedimented by means of centrifugation at 100,000g for 3 h. DNA was extracted from the pellet with phenol-chloroform and resolved in 10 mL of distilled water. With use of an aliquot (1 mL) of DNA solution and a PCR kit (Premix Taq PCR kit; Takara), PCR was performed with a thermocycler (model 9600; Perkin-Elmer) for 50 cycles at 94ЊC for 1 min, 55ЊC for 2 min, and 72ЊC for 1 min. The oligomers used for PCR are shown in table 1 [4] [5] [6] [7] [8] .
All PCRs were performed with the same amplification conditions, with negative controls (without DNA) added in every 5-10 samples that were not blinded.
AdV was detected by means of Southern blotting with use of the sequence of PCR product obtained from 4 AdV type 11 strains isolated from the patients with HC as the probe (table  1) . The sequence of this probe differed in 4 positions from the published data, as is shown in table 1 [8] . Sensitivity of PCR for detection of AdV was compared with that of culture for 74 samples. Results showed that the sensitivity of PCR was 100% and the specificity was 96% in comparison with culture.
Serological evaluation for anti-adenovirus antibody. Anti-AdV antibody in pretransplantation serum was examined by means of complement fixation with serum samples obtained from patients before they underwent BMT (Denka Seiken). The type 3 GB strain of AdV was used as the antigen.
Statistical analysis. STAT View, version 4 (Abacus Concepts) was used to perform the x 2 analysis. Logistic regression was analyzed by use of JPM, version 3.0 (SAS Institute).
RESULTS
Analysis of patients with HC.
From 1986 through 1998, 282 patients underwent BMT or peripheral blood stem cell transplantation at the Tokyo Metropolitan Komagome Hospital. Among them, 45 developed HC; 1 of the 45 developed HC in association with local recurrence of leukemia and was excluded from further study.
The average age was 34.6 years (range, 16-53 years), the mean duration from the time of transplantation to the date of onset was 88.2 days (range, 10-707 days), and the mean duration of symptoms was 39.8 days (range, 3-294 days). HC developed more frequently among patients who underwent allogeneic BMT than among those who underwent autologous or syngeneic BMT (41 of 207 patients vs. 2 of 71 patients and 1 of 4 patients, respectively;
). P p .003 HC in patients who underwent allogeneic BMT. To evaluate the risk factors for HC, we examined several factors noted only in those patients with HC who had undergone allogeneic transplantation (table 2) . A total of 41 of 207 patients developed HC. In univariate analysis, donor type, primary disease, and pretransplantation serological status for anti-AdV antibody did not correlate with the incidence of HC, whereas the preparative regimen ( ), GVHD prophylaxis ( ), grade of P p .035 P p .032 acute GVHD ( ), and use of mesna ( ) did P ! .0001 P p .001 correlate with the incidence of HC. Logistic regression analysis revealed the presence of acute GVHD (grade, у2) as the most significant predictive factor for HC ( ; OR, 5.035; 95% P ! .0001 CI, 3.27-7.26). Donor type, preparative regimen, and GVHD prophylaxis were not significant factors (table 3) .
Viral cultures of urine specimens. Among the 44 patients who developed HC, urine samples were obtained for culture from 43. Twenty-six of the urine samples yielded AdV on culture, of which 22 strains were type 11. The results of 2 other cultures were positive for cytomegalovirus, but the results of the remaining 15 cultures were negative. The time of onset of HC ( ) did not differ between P p .849 patients who tested positive and those who tested negative for AdV (data not shown) or according to the duration of the symptoms ( ). Of the specimens that were obtained for P p .642 culture from patients who underwent allogeneic BMT, 24 of 41 tested positive for AdV. The results revealed that the incidence of HC with AdV correlated with GVHD prophylaxis ( ), grade of GVHD ( ), and the year that the P p .040 P p .0002 patient underwent BMT ( ), by use of univariate anal-P p .024 ysis. The incidence of HC without AdV, on the other hand, was significantly higher among patients who received marrow from unrelated donors ( ) and among those whose P p .0008 pretransplantation regimen included busulfan ( ; in P ! .0001 particular, a busulfan/cyclophosphamide/TLI regimen).
Evaluation of virus by use of PCR. Urine specimens were obtained from 26 consecutive patients who underwent allogeneic BMT from April through December 1998 (table 2). A total of 193 urine specimens were obtained from patients before and once per week for 5 weeks after they underwent BMT, followed by sampling at 8 and 12 weeks, if possible. Three samples were obtained from 3 patients while HC progressed. In addition, 14 available urine samples from 19 patients with HC who underwent transplantation from July 1995 through February 1998 were evaluated by use of both PCR and viral culture. Eight (57.1%) of them were known to be positive for AdV by means of viral culture.
In 190 samples obtained from patients without HC, ∼30% of the specimens tested positive for BKV (58 samples) and JCV (55 samples), and 5 samples (3%) tested positive for AdV. Urine samples obtained from patients without HC did not reveal occult blood in urinalysis, with the exception of 1 sample that was obtained from a patient with a history of chronic glomerulonephritis. For the 3 samples obtained from patients with HC, the number of positive results for BKV, JCV, and AdV were 3, 1, and 1, respectively. When we added the results of another 14 samples obtained from patients with HC, the numbers of positive results became 14 of 17, 9 of 17, and 10 of 17, respectively. These rates of incidence were significantly higher than were those for the specimens obtained from the patients without HC ( , , and , respectively). P ! .0001 P p .026 P ! .0001 Among 7 patients with AdV-negative HC that had been revealed by use of PCR, BKV was detected in 7 and JCV was detected in 3. No other virus was detected by means of viral culture.
DISCUSSION
HC is a rather devastating complication of BMT; it not only negatively affect's the patient's quality of life because of pain and discomfort caused by the manipulations required for treatment, but it also may lead to death. Early-onset HC has been considered to be an effect of treatment with medications such as cyclophosphamide, and late-onset HC is usually thought to be the result of viral infection.
Bedi et al. [1] reported that the rate of incidence of HC was similar among patients who received mesna or diuresis and those who received allogeneic transplants (27%) or autologous marrow transplants (23%). In contrast, Kondo et al. [9] reported that, in their institution, the risk factors for HC were allogeneic hematopoietic stem cell transplantation, advanced age, and the use of busulfan in the conditioning regimen. The risk factors thus remained unclear.
In our series, the incidence of HC was significantly correlated with the type of marrow and the grade of acute GVHD, but not with the patient's serological status against AdV before undergoing BMT. Seber et al. [10] found that grade II-IV GVHD, use of busulfan, and age were related to an increased risk of HC. They also reported that the incidence of HC was higher among patients who underwent allogeneic BMT than it was among patients who underwent autologous BMT [11] . Our data agree with these results in monovariate analysis.
Several reports have suggested an association between BK viruria and HC. Arthur et al. [12] identified BKV in 55% of urine samples obtained from patients during episodes of cystitis versus 11% obtained from patients during cystitis-free periods. They detected the virus by use of ELISA and DNA hybridization assay of urine specimens. More recently, Bedi et al. [1] considered the presence of BK viruria to be predictive of the incidence of HC in patients after they undergo BMT. Fifty percent of patients with persistent BK viruria developed HC, whereas those who did not excrete BK virus did not develop HC.
Although these reports suggest a relationship between BKV and HC, several others have shown that BKV viruria is not sufficient cause for HC and have discounted any relationship between the two [13] [14] [15] [16] . Azzi et al. [16] detected BKV by use of PCR in 50% of patients after they underwent BMT, but only 24% of these patients developed HC.
JCV is another polyomavirus that behaves similarly to BKV. In fact, Arthur et al. [3] investigated the significance of JC viruria in patients who underwent BMT. Whereas BKV was reactivated in 55% of BKV-seropositive patients, JCV was reactivated in only 7%, and no relationship between JCV and HC was indicated.
AdV has also been considered to be responsible for HC in patients who have undergone BMT. This virus, especially type 11, is the confirmed causal agent of HC in children [17] . MiDownloaded from https://academic.oup.com/cid/article-abstract/32/9/1325/291394 by guest on 03 April 2019 yamura et al. [2] reported that 8 of 12 patients who developed HC after undergoing allogeneic BMT excreted AdV type 11 at the onset of cystitis, whereas only 2 of 128 samples obtained from cystitis-free patients tested positive for AdV. The incidence of BKV was not evaluated.
As for BKV, however, contradictory findings have been reported. Ambinder et al. [18] found that only 5 (0.9%) of 502 patients who received a bone marrow transplant were AdV positive and that only 4 of 100 patients with HC associated with BMT had AdV type 11. Shields et al. [19] detected urinary AdV in 22 of 1051 patients who underwent BMT, and 8 of them developed HC. Another 8 patients who developed HC had AdV-negative urine, but the results of viral cultures of samples obtained from other sites were positive.
More recently, Seber et al. [10] described 208 patients with HC among 1908 bone marrow transplant recipients. AdV was found in 41 patients, and 12 of them developed severe HC, but BKV was not sought; therefore, the effect of this virus on these patients was not determined.
At our institution, AdV was isolated by means of viral culture in 60% of the urine specimens obtained from patients who developed HC. Eighty-five percent of those isolates were subclassified as type 11. This rate of incidence is quite high compared with that found at institutions in the United States, but it is consistent with that noted by Miyamura et al. in Japan [2] .
To evaluate the issue further, we investigated BKV, JCV, and AdV by means of PCR of urine samples from 26 patients. Even though there was no sign of HC or occult blood in urine, BKV was detected in ∼30% of the samples, as was JCV. There was opportunity for bias in selection of the patients; however, we still believe that these findings suggest that BKV could be excreted in urine rather frequently in patients who have undergone BMT without any evidence of hematuria or other related symptoms, as reported elsewhere [16] . The virological importance of these findings in relation to HC remains to be resolved. As was noted by Azzi et al. [16] , BKV infection alone may not necessarily lead to HC in patients who have undergone BMT, and other factors could be involved in the development of HC. The fact that the incidence of JCV did not differ from that of BKV suggests the same conclusion.
The incidence of BKV excretion was significantly higher in specimens obtained from patients with HC than in those obtained from patients without HC. However, the same tendency was also observed (but was not as significant) with regard to JCV, which suggests the possibility of increased shedding of polyomaviruses during HC.
On the other hand, the incidence of AdV among patients without HC was 3%, whereas that among patients with HC was 60%. The incidence among patients with HC was confirmed by use of 2 different methods in this study, and the positive results of viral culture were consistent with those of PCR (26 of 43 vs. 10 of 17). Because we could not differentiate viruria from pathologically confirmed viral cystitis in this study, we could not specify the agent responsible for each instance of HC, even if the urine samples tested positive for AdV and/or BKV. However, these results were consistent with those in the report by Miyamura's et al. [2] , which suggests a strong correlation between AdV in urine and the occurrence of HC after BMT.
In the patients with AdV-negative HC, we could not identify any specific pathogens. The high incidence of BKV among these patients may suggest some relationship between AdV-negative HC and BKV, but this needs further evaluation. At the same time, we could not determine any reason for the high incidence of AdV among patients with HC in our institution versus that described in other reports. The incidence of BKV in urine excludes the possibility of a low incidence of BKV infection in our patient population. Whether this discrepancy is due to a high incidence of AdV in Japan or simply due to methodological reasons remains to be resolved.
In conclusion, the presence of AdV was significantly correlated with that of HC in our patients' urine.
